South Korea’s IPO market is on track for a surge of issuance, as Doosan Bobcat and Samsung BioLogics prepare to list in the fourth quarter. Mid-caps are also lining up to float, giving a fillip to the country’s equity capital markets. Jonathan Breen reports.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.